We conducted surveillance for multidrug-resistant Plasmodium falciparum in Cambodia during [2004][2005][2006] by assessing molecular changes in pfmdr1. The high prevalence of isolates with multiple pfmdr1 copies found in western Cambodia near the Thai border, where artesunate-mefl oquine therapy failures occur, contrasts with isolates from eastern Cambodia, where this combination therapy remains highly effective.
T he Thailand-Cambodia border has been an epicenter for drug-resistant Plasmodium falciparum. Recent clinical studies indicate that effi cacy of artesunate-mefl oquine combination is decreasing on both sides of the border (1-3). In contrast, P. falciparum in eastern Cambodia remains sensitive to mefl oquine and the artesunate-mefl oquine combination (4, 5) . Declining artesunate-mefl oquine effi cacy on the Thai border and the geographic variation in susceptibility to this combination therapy suggest expanded surveillance is needed in Cambodia. An inexpensive method to help target in vivo monitoring sites is surveillance for molecular markers of drug resistance.
We have previously shown that elevated P. falciparum multidrug resistance 1 (pfmdr1) gene copy number is associated with an 8-fold risk for artesunate-mefl oquine failure in western Cambodia (6) . More recently, we conducted a molecular surveillance for pfmdr1 mutations to guide the selection of sentinel sites for in vivo monitoring of artesunate-mefl oquine resistance.
The Study
Clinical isolates of P. falciparum were collected from 5 sites across Cambodia (Figure 1 ): Pailin, Kampong Seila, Chumkiri (western), Memut, and Rattanakiri (eastern) during [2004] [2005] [2006] . Study participants included patients who were seen at health centers with uncomplicated falciparum malaria, including mixed infections. Fifty-six samples from patients in Pailin had been previously analyzed (6) . Institutional review board approvals were obtained from the Cambodian National Ethics Committee for Health Research, the US Naval Medical Research Unit No. 2, and the University of North Carolina at Chapel Hill (UNC).
Peripheral blood was used to prepare smears and fi lter paper blood spots (25 μL, 2 spots) on Whatman 3-mm blotting paper (Whatman International Ltd., Maidstone, Kent, UK) from each participant. Blood smears were examined to determine parasite density, nonfalciparum species, and gametocytes. Enrolled participants completed a questionnaire on demographic information and past medical history. They received artesunate-mefl oquine in accordance with national guidelines for uncomplicated falciparum malaria. DNA was extracted from blood spots by using QIAmp Mini kits (QIAGEN, Valencia, CA, USA). pfmdr1 copy number and single-nucleotide polymorphism assays were performed as previously described (6, 7) , except that in pfmdr1 single-nucleotide polymorphism assays the concentration of probes was reduced from 250 nM to 125 nM and reactions were not duplicated.
Linear regression was used to determine if pfmdr1 copy number varied by site. pfmdr1 copy number was in- verse transformed to meet assumptions of normality and homoscedasticity. Backwards elimination based on a p value of 0.05 was used to determine the effect of site when controlling for confounders. Logistical regression was used to confi rm the results of the linear regression analysis by using a cutoff of 1.5 copies (8) . Logistic regression was also used to determine if pfmdr1-184 genotype varied by site. Samples with a mixture of 184-phe and 184-tyr were coded as 184-phe. All statistical analyses were conducted in Stata 8.2 (StataCorp, College Station, TX, USA). We enrolled 744 study participants with uncomplicated P. falciparum malaria. The characteristics of participants at each site are described in Table 1 . pfmdr1 copy number was successfully determined for 712 (95.7%) of 744 samples. When compared with results at UNC, results of copy number assays performed by the National Malaria Control Program (NMCP) staff in Phnom Penh were slightly lower (mean difference -0.163, 95% confi dence interval [CI] -0.277 to -0.049, n = 44), and the 2 groups were in 100% concordance with distinguishing samples with >2 pfmdr1 copies.
pfmdr1 copy numbers ranged from 0.6 to 6.3, and 167 (23.5%) of 712 samples had >1.5 copies. The median and distribution of pfmdr1 copy number varied by site and were highest in the 3 western Cambodian sites (Figure 2 ). The proportion of samples with >1.5 pfmdr1 copies was greater in western than eastern Cambodia (52.7% vs. In univariate and multivariate linear regression models, site was the strongest predictor of pfmdr1 copy number. Chumkiri had the highest pfmdr1 copy number before and after clinical correlates were controlled for ( Table 2) . The relationship between copy number and site was retained when the analysis was repeated with logistic regression. Compared with Rattanakiri, the OR of having a copy number >1.5 was 32.4 (95% CI 16.4-64.2) for Chumkiri, 7.8 (95% CI 4.3-13.9) for Pailin, and 0.5 (95% CI 0.2-1.2) for Memut when parasitemia and year were controlled for.
Conclusions
We found geographic heterogeneity for 2 pfmdr1 genetic markers: pfmdr1 184 and pfmdr1 amplifi cation. Genotype 184-Phe was associated with pfmdr1 amplifi cation at the population level but not in individual isolates. The basis of this trend is unknown. Pailin, Kampong Seila, and Chumkiri in western Cambodia had higher pfmdr1 copy numbers and higher prevalence of pfmdr1 184-Phe 3 (1-6) 4 (2-6) 6 (1-6) 4 (2-6) 4 (0-6) *The missing values by category include parasitemia (n = 4), gametocytemia (n = 4), smear-positive malaria in past year (n = 160), antimalarial drug taken in past month (n = 56), mixed infection (n = 4), and no. of d of illness (n = 21). †Baseline differences were most likely due to small sample size. ‡Parasites/ L. than Memut and Rattanakiri in eastern Cambodia. An association between these markers and resistance is consistent with reports of reduced effi cacy of artesunate-mefl oquine in Pailin (79% over 42 days) (2) compared with Memut and Rattanakiri, where artesunate-mefl oquine effi cacy remains close to 100% (4, 5) . This fi nding is also consistent with the decrease of mefl oquine sensitivity in western Cambodia based on in vitro drug susceptibility monitoring conducted by the Pasteur Institute of Cambodia from 2001 through 2007 (9,10; P. Lim, pers. comm.). Chumkiri was surveyed because local health staff observed that falciparum malaria patients treated with artesunate-mefl oquine often returned within weeks with recurrent fever and parasitemia. The possibility of such resistance in this site was particularly alarming because it was thought to be confi ned to Thailand-Cambodia border areas. Chumkiri had not previously been a sentinel site for antimalarial effi cacy monitoring by NMCP. On the basis of these pfmdr1 data, a clinical trial of artesunatemefl oquine was launched in Chumkiri in 2006 (11) . Clinical validation of predicted resistance by in vivo studies is beyond the scope of this study, although multiple in vitro and in vivo studies have consistently shown an association of increased pfmdr1 copy number with mefl oquine or artesunate-mefl oquine failure in Southeast Asia (8, 10, (12) (13) (14) (15) , supporting use of pfmdr1 copy number in routine surveillance and policy formation.
Monitoring changes in antimalarial drug effi cacies is essential for guiding treatment policies in an era of multidrug resistance. However, such studies are resource intensive. In Cambodia, for example, NMCP can conduct in vivo studies at only 2-3 sites per year because of limited funds and trained staff. Molecular markers can help target in vivo studies where they are most needed. Molecular surveillance is high-throughput and can be performed in a central laboratory on dried blood spots. Expanded surveillance allows for molecular mapping and enables a rapid containment of resistance foci. pfmdr1 assays are now routinely performed in Cambodia by NMCP staff. National and regional molecular surveillance by malaria-endemic countries is a real possibility. 
